Program 2001
    

 

 

The 24th European Lipoprotein Club (ELC) Meeting

will take place at the Evangelische Akademie, Tutzing, near Munich

From September 10-13, 2001

Final Program

 

Monday, September 10

 

20.00              State of the Art Lecture, Chair: H. Dieplinger

            F. Lottspeich (Munich)

            Proteomics – State of the Art

 

Tuesday, September 11

 

Session I: Atherogenic Mechanisms, Chairs: M. Hofker, D. Bowyer

 

8.30-9.15            S. Fazio (Nashville, TN)

The arterial macrophage: So much more than a garbage collector

9.15-9.35            L. Havekes (Leiden)

The role of the tumour suppressor gene p53 in the progression and             regression of atherosclerotic lesions

9.35-9.55            M. Gijbels (Maastricht)

Genetic deletion of tissue plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis

9.55-10.15            M. De Winther (Maastricht)

Mouse model to study the role of snpPLA2 in atherogenesis

10.15-10.45            Coffee break

10.45-11.05            N. Leitinger (Vienna)

Influence of oxidised phospholipds on inflammatory gene induction in endothelial cells

11.05-11.25 A. Stannard (London)

Cell-derived apolipoprotein E stimulates nitric oxide synthase (NOS) and inhibits vascular cell adhesion molecule-1 (VCAM-1) in human endothelial cells

11.25-11.45            D. Milosavljevic (Paris)

Elevated expression of LDL receptor related protein, CLA-1 and SRA scavenger receptors in human monocyte-derived macrophages: role in foam-cell formation

11.45-12.05            M. Klouche (Stuttgart)

Expression of pentraxin-3 (PTX3) by human vascular smooth muscle cells – synergistic action of degraded lipoproteins and classic acute-phase proteins

12.30              Lunch

 

16.00-18.00            Wine & Science (Poster Session)

 

Session II: Regulation of cellular cholesterol homeostasis, Chair: H. Dieplinger, P. Tarugi

 

19.30-20.00            R. Lawn (Palo Alto, CA)

ABCA1: The gatekeeper for eliminating excess tissue cholesterol

20.00-20.20             A. von Eckardstein (Münster)

The ATP binding cassette transporter A1 contributes to the secretion of interleukin-1b from macrophages, but not from monocytes

20.20-20.40            Y. Uehara (Münster)

Regulation of the ATP binding cassette transporter A1 (ABCA1) by insulin

20.40-21.00            F. Kuipers (Groningen)

Hepatic synthesis and hepatobiliary transport of cholesterol are not affected in ABCA1-deficient mice

21.00-21.20 S. Lorkowski (Münster)

The ATP-binding cassette transporter gene ABCG1 (ABC8) is overexpressed in Tangier disease macrophages

21.20-21.40 C. Langer (Münster)

Testerone stimulates selective cholesteryl ester uptake in hepatocytes and efflux from macrophages

21.40-22.00            D. Delsing (Leiden)

Expression of apolipoprotein C1 in macrophages reduces cholesterol esterification and enhances cholesterol efflux

 

Wednesday, September 12

 

Session III: Structure/function relationship of lipoproteins

Chair: P. Talmud, M. Jauhiainen

 

8.30-9.15            R.O. Ryan (Oakland, CA)

Structural studies on helix bundle molecular switch apolipoproteins

9.15-9.35            M. Baumstark (Freiburg)

Structure of human LDL subfractions using X-ray crystallography

9.35-9.55            G. Olivecrona (Umea)

Studies of apolipoprotein C-II by NMR and site-directed mutagenesis. Identification of residues in a helical region important for activation of lipoprotein lipase

9.55-10.15            C. Labeur (Gent)

Characterization of recombinant wildtype and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of apoE and inhibition of lipoprotein lipase

 

Coffee Break

 

10.45-11.00            M. Jauhiainen (Helsinki)

The inactive form of human plasma PLTP: isolation and partial characterization       

11.00-11.15            F. Peelman (Gent)

A hydrophobic cluster at the surface of the human plasma phospholipid transfer protein is critical for activity on high density lipoprotein substrates

11.15-11.35            G. Sperber (London)

Chimeraplasts as reagents to probe structure-function relationships in ApoA-I and LCAT

11.35-11.55            P. Kovanen (Helsinki)

Chymase proteolyzes apoA-I in discoidal reconstituted HDL particles by cleaving the amino- and carboxy-termini: implications for the mechanism of cellular cholesterol efflux induced by lipidated apoA-I

 

12.30 Lunch

 

Session IV: Gene regulation in atherosclerosis, Chair: H. Funke, B. Staels

 

14.00-14.45            B. Staels (Lille)

Nuclear receptors controlling lipid metabolism and inflammation in the vascular wall

14.45-15.05            B. Weitkamp (Münster)

Gene expression with defined cell populations collected from atherosclerotic plaques by laser capture microdissection and quantification of gene expression by real-time PCR

15.05-15.25            A. Kreeft (Leiden)

Expression profiling to identify novel dietary response genes involved in lipid metabolism

 

15.25-15.55               Coffee Break

 

15.55-16.15            A. Verhoeven (Rotterdam)

The hepatic lipase 514 C->T polymorphism interferes with the stimulation of gene expression by NEFA‘s

16.15-16.35            S. Humphries (London)

Functional effects of interleukin-6 (IL6) promoter polymorphisms in vivo and in vitro

16.35-16.55               G. Tan (Oxford)

Subcutaneous adipose tissue function in a subject with a dominant negative PPARg mutation (PPARgP467L)

16.55-17.15               J. Chinetti (Lille)

PPAR-alpha controls cholesterol homeostasis in human monocyte-derived macrophages

 

20.00              Social Event

 

Thursday, September 13

 

Session V: Insulin resistance, NEFA’s and obesity, Chair: J. Nimpf, G. Dallinga-Thie

 

9.00-9.45            R. Farese (San Francisco, CA)

Triglyceride synthesis and obesity: insights from DGAT-deficient mice

9.45-10.05    D. Chirieac (Rochester, NY)

Selective resistance to insulin-mediated supression of very low density lipoprotein production in Zucker diabetic fatty rats

10.05-10.25            J. Strauss (Graz)

EL mediates HDL binding, particle and selective uptake in HepG2 cells

10.25-10.45  G. Hämmerle (Graz)

The in vivo role of hormone-sensitive lipase (HSL) in lipid mobilisation

10.45-11.05  P. Voshol (Leiden)

No altered glucose uptake but increased glucose oxidation in hormone sensitive lipase knockout mice

 

11.05-11.35            Coffee break and Young Investigator award

 

11.35-11.55            F. Van’t Hooft (Stockholm)

Human evidence that the apolipoprotein A-II gene is implicated in visceral fat accumulation, metabolism of triglyceride-rich lipoproteins and protection against early atherosclerosis

11.55-12.15  J. Björkegren (San Francisco, CA)

Microsomal triglyceride transfer protein and hepatic toxicity

 

12.30 Lunch


+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

If you wish to attend this year's Meeting, please complete the  abstract form as shown below and return to:

Hans Dieplinger
Secretary, Lipoprotein Club
Institute of Medical Biology and Human Genetics
University of Innsbruck
Schoepfstrasse 41
A-6020 Innsbruck, Austria
Fax: 43-512-507-2861
Tel: 43-512-507-3452
e-mail: Hans.Dieplinger@uibk.ac.at

1) FIND AN EXAMPLE OF THE ABSTRACT FORM AND THE GUIDELINESS FOR SUBMISSION BELOW

2) Please request an original form (MS-Word file) by E-mail from any of the committee members or click HERE for the version in PDF format.  or the MS-word format

3) MAIL THE COMPLETED FORM TO OUR SECRETARY (also FAXES, OR E-MAIL FORMS ACCEPTABLE, but regular mail is still preferred)

________________________example - do not copy this form _________________________________________

24th ELC Meeting

September 10-13, 2001     Deadline May 1st, 2001!!!

 Applicant (use separate form for each applicant):

Family Name:.......................................... First Name:..............................Sex: F / M

Address:.........................................................................................................................

Telephone number:...............................Faxnumber:...............................................

e-mail (obligatory):....................................................................................................

This abstract is for session number I / II / III / IV/other Other (please circle)

Abstract of proposed presentation (keep the length of the abstract within this page (i.e. one page A4 format) for all text including the heading above)

 

 

 

 

 

 

Please include here 4-5 key words describing your research interest.

.........................................................................................................................

____end of page_______________________________________________

 

EUROPEAN LIPOPROTEIN CLUB

GUIDELINES FOR SUBMISSION OF ABSTRACTS

 

The primary purpose of the ELC is to promote discussion and exchange of ideas on the chosen topics. In recent years the number of applications for the ELC has increased considerably, but because of the size of the lecture room and the accommodation available, the number of people attending the conference is strictly limited. Because applicants are chosen on the basis of the abstracts they submit, the following guidelines have been drawn up by the  Committee.

 1. The abstract should comprise: A) a brief title of not more than 20 words or two lines; B) the names of the authors involved in the work; C) a brief identification of the Institute (Affiliation) of the authors; D) the objectives of the study; E) the results obtained; F) the conclusion of the study. In addition, the requested information on the abstract form  must be completed with the name of presenter (which will appear on the  badge), the full address for correspondence, including telephone + fax numbers and e-mail adress, and the topic under which the abstract is being presented. Applications which do not fit the topics are also worthy of consideration, provided that a brief summary of the applicant’s research work is added in the abstract form; applications without this information will not be considered for participation in the meeting.

2. All abstracts are rated/graded by the Committee members, and applications are exclusively chosen on the scientific merit of the work. Abstracts not strictly related to the topics will be considered for possible participation in a varia session.

3. Only a few of the chosen applicants will be invited to present their work, but all those invited are expected to participate in the general discussion of the presentations.

4. The Committee feels that discussion and exchange of ideas is best promoted by having people with a wide range of experience and expertise at the Meeting, and that as many different laboratories should by represented. Because of this, in general, some of multiple applications from a single laboratory are unlikely to be rated highly.

5. The Committee also feels that good discussion is promoted by having the widest possible range of countries represented at the conference. For this reason, where similar abstracts are competing for a place, consideration to country of origin may be taken into account.

6. Because of the timing of the grading and selection procedure, abstracts received after the deadline of 1st May will not be accepted.

7. The selection of abstracts takes place at a Committee meeting in June, and those selected will be informed soon after by the Secretary. Those selected to give an  oral presentation of their work will be contacted by the session Chairpersons.

8. Selected applicants are expected to stay for the full length of the meeting.

9. A "waiting list" of applicants, whose abstracts scored below the cut-off point, is kept by the Secretary. If any places become vacant, individuals on this list will be approached.

10. All abstracts are treated as confidential by the Committee members and are not published. However, after the meeting in September the session Chairpersons prepare a report, based on the presentations, which will be published in Atherosclerosis. If this creates a conflict for any of the speakers, they should discuss the situation with the Chairpersons of their session beforhand